Compare SLDP & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDP | ATYR |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | 230 | 58 |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 714.7M | 73.7M |
| IPO Year | N/A | N/A |
| Metric | SLDP | ATYR |
|---|---|---|
| Price | $2.92 | $0.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 8 |
| Target Price | ★ $7.00 | $4.20 |
| AVG Volume (30 Days) | ★ 3.1M | 985.5K |
| Earning Date | 05-05-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $0.64 |
| 52 Week High | $8.86 | $7.29 |
| Indicator | SLDP | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 30.18 | 37.34 |
| Support Level | N/A | $0.67 |
| Resistance Level | $3.48 | $0.85 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 4.10 | 1.23 |
Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).